Influence of carbapenem resistance on mortality of patients with Pseudomonas aeruginosa infection: A meta-analysis

Abstract

Treatment of infectious diseases caused by the carbapenem-resistant Pseudomonas aeruginosa (CRPA) is becoming more challenging with each passing year. We conducted a meta-analysis to assess the impact of carbapenem resistance on mortality of patients with P. aeruginosa infection. We searched PUBMED, Web of science, EMBASE, Google Scholar and the Cochrane Library up to December 25, 2014, to identify published cohort or case-control studies. 17 studies, including 6660 patients carrying P. aeruginosa, were identified. The pooling analysis indicated that patients infected with CRPA had significantly higher mortality than those infected with carbapenem-susceptible P. aeruginosa (CSPA) (crude OR €‰= €‰1.64; 95%CI €‰= €‰1.40, 1.93; adjusted OR €‰= €‰2.38; 95%CI €‰= €‰1.53, 3.69). The elevated risk of mortality in patients with CRPA infection was not lessened when stratified by study design, sites of infection, or type of carbapenem, except that the estimate effect vanished in CRPA high-incidence region, South America (crude OR €‰= €‰1.12; 95%CI €‰= €‰0.64, 1.99). Begg € s (z €‰= €‰0.95, p €‰= €‰0.34) and Egger € s test (t €‰= €‰1.23, p €‰= €‰0.24) showed no evidence of publication bias. Our results suggest that carbapenem resistance may increase the mortality of patients with P. aeruginosa infection, whether under univariate or multivariate analysis.